Atriva Therapeutics to Speed up Development of COVID-19 Drug with Federal Funding
Product candidate ATR-002 could help hospital patients with COVID-19 avoid ventilation and intensive care treatment
27-Apr-2021 -
Atriva Therapeutics GmbH has secured up to €11.4 million in federal funding. The company, founded in 2015, announced today that it was selected for research funding from the German Federal Ministry of Education and Research (BMBF). Atriva will use the funds to advance its drug ATR-002 towards ...
coronaviruses
Covid-19
research grants
+1